Kymera CFO sells shares, exercises stock options
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of stock option exercises and share sales in Kymera Therapeutics, Inc. common stock.
Rhea-AI Filing Summary
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of stock option exercises and share sales in Kymera Therapeutics, Inc. common stock. On June 30, 2026, he exercised options to acquire 61,378 shares at an exercise price of $5.33 per share and then sold 77,109 shares in open-market transactions. The sales occurred in multiple trades at weighted average prices within ranges from $110.37 to $118.09 per share, as detailed in the price footnotes. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 23, 2026, indicating they were scheduled in advance. Following the transactions, Jacobs directly holds 244,883 shares of Kymera common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
Jacobs Bruce N.
Role
Chief Financial Officer
Sold
77,109 shs ($8.86M)
Approx. gross sale proceeds
$8.86M
Approx. exercise cost
$327K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 61,378 | $0.00 | $0.00 |
| Exercise | Common Stock | 61,378 | $5.33 | $327K |
| Sale | Common Stock | 1,500 | $110.5397 | $166K |
| Sale | Common Stock | 1,700 | $111.5671 | $190K |
| Sale | Common Stock | 1,100 | $112.7881 | $124K |
| Sale | Common Stock | 4,110 | $114.1875 | $469K |
| Sale | Common Stock | 51,375 | $114.7696 | $5.90M |
| Sale | Common Stock | 7,971 | $115.8171 | $923K |
| Sale | Common Stock | 6,153 | $116.9937 | $720K |
| Sale | Common Stock | 3,200 | $117.7029 | $377K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 244,883 shares (Direct)
Footnotes (11)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.
- F2. This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. The shares underlying this stock option are fully vested and exercisable.
Key Figures
Shares sold: 77,109 shares
Options exercised: 61,378 shares
Option exercise price: $5.33 per share
+2 more
5 metrics
Shares sold
77,109 shares
Open-market sales on June 30, 2026
Options exercised
61,378 shares
Stock option exercise on June 30, 2026
Option exercise price
$5.33 per share
Exercise price for 61,378-share option
Post-transaction holdings
321,992 shares
Common stock held directly after transactions
Sale price ranges
$110.37–$118.09 per share
Ranges of sale prices noted in footnotes
Key Terms
Rule 10b5-1 trading plan, weighted average price, employee stock purchase plan, Stock Option (Right to Buy), +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase plan financial
"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... The shares underlying this stock option are fully vested and exercisable."
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kymera Therapeutics (KYMR) CFO Bruce Jacobs report in this Form 4?
Kymera CFO Bruce N. Jacobs exercised stock options for 61,378 shares at $5.33 and sold 77,109 common shares in multiple open-market trades. All transactions occurred on June 30, 2026 and were disclosed as routine insider activity.
Did the Kymera (KYMR) CFO exercise stock options in this filing?
Yes. Bruce N. Jacobs exercised stock options covering 61,378 shares of Kymera common stock at an exercise price of $5.33 per share. A related derivative entry shows the corresponding stock option position reduced to zero following this exercise event.
What do the weighted average price footnotes mean in the Kymera (KYMR) Form 4?
Each sale line shows a single weighted average price, but a footnote explains shares were sold in many trades within specified ranges, such as $110.37 to $110.96. The insider offers to provide exact trade-by-trade prices upon request to investors or regulators.
AI-generated analysis. How Rhea-AI works. Not financial advice.
